MedTrace Logo

Thiamine Supplementation in Patients With Septic Shock

NCT03122678 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-03-15

No results posted yet for this study

Summary

To determine if intravenous thiamine would decrease the time to reversal of shock in patients with septic shock.

Conditions

  • Septic Shock
  • Shock, Septic
  • Lactic Acidosis
  • Thiamine Deficiency

Interventions

DRUG

Thiamine

DRUG

Placebos

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Jinesh Mehta, MD · Cleveland Clinic Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-05
Primary Completion
2019-03-14
Completion
2019-03-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03122678 on ClinicalTrials.gov